These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 24152333)
1. Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome. Potier MC; Braudeau J; Dauphinot L; Delatour B CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):8-15. PubMed ID: 24152333 [TBL] [Abstract][Full Text] [Related]
2. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists. Martínez-Cué C; Delatour B; Potier MC Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222 [TBL] [Abstract][Full Text] [Related]
3. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554 [TBL] [Abstract][Full Text] [Related]
4. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Rueda N; Flórez J; Martínez-Cué C Neurosci Lett; 2008 Mar; 433(1):22-7. PubMed ID: 18226451 [TBL] [Abstract][Full Text] [Related]
5. Rescue of deficient amygdala tonic γ-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel γ-aminobutyric acid type A receptor-positive allosteric modulator. Martin BS; Martinez-Botella G; Loya CM; Salituro FG; Robichaud AJ; Huntsman MM; Ackley MA; Doherty JJ; Corbin JG J Neurosci Res; 2016 Jun; 94(6):568-78. PubMed ID: 26308557 [TBL] [Abstract][Full Text] [Related]
6. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Lewis DA; Volk DW; Hashimoto T Psychopharmacology (Berl); 2004 Jun; 174(1):143-50. PubMed ID: 15205885 [TBL] [Abstract][Full Text] [Related]
7. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome. Zorrilla de San Martin J; Delabar JM; Bacci A; Potier MC Free Radic Biol Med; 2018 Jan; 114():33-39. PubMed ID: 28993272 [TBL] [Abstract][Full Text] [Related]
8. The Role of Phospholipase C in GABAergic Inhibition and Its Relevance to Epilepsy. Kim HY; Suh PG; Kim JI Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808762 [TBL] [Abstract][Full Text] [Related]
9. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Garcia-Alloza M; Tsang SW; Gil-Bea FJ; Francis PT; Lai MK; Marcos B; Chen CP; Ramirez MJ Neurobiol Aging; 2006 Aug; 27(8):1110-7. PubMed ID: 15996794 [TBL] [Abstract][Full Text] [Related]
11. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Begenisic T; Baroncelli L; Sansevero G; Milanese M; Bonifacino T; Bonanno G; Cioni G; Maffei L; Sale A Neurobiol Dis; 2014 Mar; 63():12-9. PubMed ID: 24269730 [TBL] [Abstract][Full Text] [Related]
15. Betaine attenuates memory impairment after water-immersion restraint stress and is regulated by the GABAergic neuronal system in the hippocampus. Kunisawa K; Kido K; Nakashima N; Matsukura T; Nabeshima T; Hiramatsu M Eur J Pharmacol; 2017 Feb; 796():122-130. PubMed ID: 27940054 [TBL] [Abstract][Full Text] [Related]